Simon Dumesnil is Director of Pasithea Therapeutics Corp.. Currently has a direct ownership of 50,000 shares of KTTA, which is worth approximately $129,000. The most recent transaction as insider was on Nov 17, 2022, when has been sold 40,000 shares (Common Stock) at a price of $1.06 per share, resulting in proceeds of $42,400. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 50K
0% 3M change
0% 12M change
Total Value Held $129,000

Simon Dumesnil Transaction History

Date Transaction Value Shares Traded Shares Held Form
Nov 17 2022
BUY
Grant, award, or other acquisition
$42,400 $1.06 p/Share
40,000 Added 44.44%
50,000 Common Stock
Nov 15 2022
BUY
Grant, award, or other acquisition
$10,700 $1.07 p/Share
10,000 Added 50.0%
10,000 Common Stock
SD

Simon Dumesnil

Director
Miami Beach, FL

Track Institutional and Insider Activities on KTTA

Follow Pasithea Therapeutics Corp. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KTTA shares.

Notify only if

Insider Trading

Get notified when an Pasithea Therapeutics Corp. insider buys or sells KTTA shares.

Notify only if

News

Receive news related to Pasithea Therapeutics Corp.

Track Activities on KTTA